SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's earnings and future prospects are currently a hot topic, with community members debating the impact of recent financial results, particularly regarding margins and revenue. Discussions also revolve around Tesla's ambitious ventures in AI, robotaxis, and robotics, as well as the potential for these initiatives to drive future growth amid increasing competition and a changing market landscape. The community is closely watching for updates on these developments and their impact on the company's valuation.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as the community discusses a potential US government equity stake in quantum computing companies, including D-Wave. Some investors believe this could legitimize the technology and attract further investment, while others are wary of a potential pump and dump scheme. The stock's recent volatility, including a sharp decline, has also fueled discussion about potential short squeezes and future prospects.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp ($LAES) is trending as discussions revolve around a potential short squeeze, driven by its position in the quantum security sector and recent news, possibly related to Trump administration interest in quantum firms. The community is actively debating the likelihood of a squeeze, analyzing short interest data, and assessing the company's prospects in light of government initiatives. Some traders express bullish sentiment, citing the company's chip technology and potential for growth.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Global X Dow 30 Covered Call ETF ($DJIA) is trending as investors discuss market momentum, potential trade war impacts, and upcoming economic data. Community members are actively debating whether the ETF will break through resistance levels, reach new targets, or face a significant correction. Discussions also include the Fed's potential rate decisions and their effect on various sectors.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

SLMT is trending due to its low float and high short interest, leading to speculation about a potential short squeeze, with some traders eyeing a move towards triple digits; the community is actively discussing its squeeze potential and technical indicators. The stock's connection to Solana is also a key talking point, with some believing that a rebound in Solana could positively impact SLMT.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending as community members debate its potential, particularly regarding its connection to Japan's digital ID initiatives and partnerships with major corporations like Sony and Panasonic. Discussions range from those who see it as a long-term infrastructure play for smart cities and data ownership, while others express skepticism and frustration over its price action and perceived lack of progress. The coin's volatile price movements and the impact of broader market trends, like Bitcoin's fluctuations, are also central to the conversation.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals ($ARMP) is trending due to promising Phase 2a trial data for its AP-SA02 drug, which showed strong efficacy against S. aureus bacteremia; retail traders are piling in, driving significant volatility as they discuss the potential of phage therapy. Community members are actively debating whether the stock will stabilize or fall back to pre-rally levels, while also noting the company's backing by Innoviva and US government funding.

Imperial Petroleum, Inc. is a ship-owning company, which engages in providing petroleum products and crude oil seaborne transportation services. It offers international seaborne transportation services to oil producers, refineries, and commodities traders. It has a fleet of three medium range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals, and one Aframax tanker which is used for carrying crude oil. The company was founded on May 14, 2021 and is headquartered in Athens, Greece.

Imperial Petroleum Inc

IMPP is trending due to increased interest in oil stocks and potential benefits from rising tanker rates amid geopolitical tensions. Community discussions focus on fleet expansion, short squeeze potential, and the impact of oil price volatility on energy transport stocks. Some investors express frustration with management's decisions and the stock's historical performance.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

Beasley Broadcast Group ($BBGI) is trending due to its low float, leading to speculation of a potential short squeeze similar to other recent runners. Community members are discussing the stock's chart setup and anticipating a breakout, with some setting ambitious price targets. However, some are cautioning about the company's financials, citing concerns about debt and revenue.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as traders analyze its potential breakout and resistance levels, while some discuss its AI advancements and partnerships, such as with DoorDash and Salesforce. Community members are actively debating whether the stock can sustain its upward momentum amid broader market concerns and competition from companies like OpenAI. Recent analyst upgrades and the anticipation of upcoming earnings are also fueling interest in GOOGL.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?

The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Tesla, AeroVironment and Progress Software fall premarket; MSC Industrial rises

Investing.com -- U.S. stock futures slipped lower Tuesday, dropping back from record levels as investors digested the latest news on trade deals, the Trump administration’s tax bill as well as upcoming key economic data.

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy type 1 (DM1).Dyne said it will now use video hand opening time (vHOT) as the primary endpoint, which measures the change from baseline in middle finger myotonia at six months compared to placebo.&nbsp;The update follows a Type C meeting with the U.S. Food and Drug Administration, which agreed vHOT could serve as an intermediate clinical endpoint to support a future submission for accelerated approval.The revised protocol was submitted to the FDA earlier this month.&nbsp;Dyne plans to complete enrollment in the expansion cohort during the fourth quarter, with 60 participants randomized 3:1 to receive either DYNE-101 or placebo.The revised expansion cohort will consist of 60 participants, randomized 3:1 to receive DYNE-101 at 6.8 mg/kg every eight weeks or placebo.&nbsp;Secondary endpoints include measures of muscle strength, walking performance, splicing biomarkers, and patient-reported outcomes.&nbsp;Enrollment is expected to be completed in Q4 2025, with pivotal data expected in mid-2026.Data from the 12-month cohort of the MAD study showed sustained effects on all measures, including vHOT and strength testing, where patients improved by 20% from baseline.&nbsp;The company also reported a favorable safety profile, with no treatment-related serious adverse events in the 56 participants dosed to date.Dyne plans to initiate a confirmatory Phase 3 trial in early 2026.&nbsp;It also reiterated that its cash balance of $677.5 million as of March 31 will fund operations into Q4 2026.Stifel analyst Paul Matteis said the change “comes as a surprise” and “will raise questions,” though he maintained a ‘Buy’ rating on the stock, suggesting the move could offer a clearer approval route.&nbsp;Meanwhile, H.C. Wainwright called the change “encouraging,” noting that powering the trial to 60 participants could improve confidence in vHOT and help detect trends across secondary endpoints.Chardan Capital also reiterated a ‘Buy’ rating and said the FDA’s confirmation of an accelerated pathway “more than offsets” a potential six-month delay to a Biologics License Application (BLA).&nbsp;The firm described the pullback as an “attractive entry point,” with the stock down 41% year-to-date.On Stocktwits, retail sentiment was ‘bullish’ amid ‘extremely high’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial

The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes. 

Equity

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Current Price	$16.35
Prev Close	$16.75
Open	$16.75
Dividend Yield	0.00%
50-Day Moving Average	$13.60
Beta	1.61
Avg. Volume	2.45M
PE Ratio	-4.23

52-Week High	$35.68
52-Week Low	$6.36
Market Capitalization	$2.33B
EPS (Annual)	-$3.37
Price to Book	3.27
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

DYN
Dyne Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DYN News

DYNDyne Therapeutics Inc